Skip to main content
Premium Trial:

Request an Annual Quote

HGS Sends New Genomics-Derived Drug To Clinical Testing

Premium

ROCKVILLE, Md.--Human Genome Sciences here has announced what it claims is the first genomics-derived drug to enter clinical testing. The company filed an Investigational New Drug (IND) application last month and will soon begin enrolling patients in a Phase I study of a human protein that may improve chemotherapy treatments.

"We believe MPIF-1 is a dual first for HGSI, the first genomics-derived therapeutic product candidate to enter clinical trials and our first IND. We expect that there will be many more IND's to follow, from Human Genome Sciences and others," commented William Haseltine, the company's chairman and CEO. The company called MPIF-1 "the tip of a very large iceberg" of Human Genome Sciences' potential therapeutic products based on genome technology.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.